Fourth quarter 2023 GAAP net loss of $(9.2) million or $(0.45) per basic weighted average common share andDistributable Earnings(1)of $10.0 million […]
BALTIMORE, March 07, 2024 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused […]